Viktor Grünwald, MD, PhD, University Hospital Essen, details the CLEAR study as well as the subgroup analysis on the efficacy of lenvatinib plus pembrolizumab for patients with aRCC. He also comments on how the available combination approaches compare for frontline aRCC, and whether there are discernable differences that separate any combination as superior in this setting.
